Sep 21, 2023 7:00 am EDT Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
Sep 18, 2023 7:00 am EDT Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa
Sep 14, 2023 7:01 am EDT Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa
Sep 1, 2023 7:00 am EDT Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27
Aug 29, 2023 1:43 pm EDT Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases
Aug 23, 2023 7:00 am EDT Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis
Aug 16, 2023 7:00 am EDT Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Aug 8, 2023 8:33 am EDT Q2 Business Update: View Kiora's Latest Presentation Detailing Our Sharpened Focus on Orphan Retinal Disease